Inactive Instrument

News Allarity Therapeutics, Inc. Nasdaq Stockholm

Equities

ALLR

US0167441049

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)	Apr. 17	AQ
Top Premarket Gainers	Apr. 15	MT
Top Premarket Gainers	Apr. 12	MT
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split	Apr. 04	MT
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split	Apr. 04	AQ
Transcript : Allarity Therapeutics, Inc. - Shareholder/Analyst Call	Apr. 01
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	Mar. 27	AQ
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	Mar. 27	CI
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)	Mar. 25	AQ
Allarity Therapeutics : Material Agreement - Form 8-K	Mar. 20	PU
Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding	Mar. 13	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update	Mar. 08	AQ
Allarity Therapeutics, Inc. Announces Termination of Marie Foegh as Chief Medical Officer	Mar. 04	CI
Allarity Therapeutics to Present at Biomarkers 2024	Feb. 28	AQ
Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP	Feb. 12	CI
Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board	Feb. 01	CI
Allarity Therapeutics, Inc. announced that it expects to receive $0.8 million in funding from 3i, LP	Jan. 17	CI
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor	Dec. 12	AQ
Allarity Therapeutics Announces Executive Changes	Dec. 12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Allarity Therapeutics, Inc. Nasdaq Stockholm

Equities

ALLR

US0167441049

Summary

Filters